Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice

Int J Nanomedicine. 2024 Aug 6:19:8029-8042. doi: 10.2147/IJN.S464720. eCollection 2024.

Abstract

Purpose: Heterologous immunization using different vaccine platforms has been demonstrated as an efficient strategy to enhance antigen-specific immune responses. In this study, we performed a head-to-head comparison of both humoral and cellular immune response induced by different prime-boost immunization regimens of mRNA vaccine and adjuvanted protein subunit vaccine against varicella-zoster virus (VZV) in middle-aged mice, aiming to get a better understanding of the influence of vaccination schedule on immune response.

Methods: VZV glycoprotein (gE) mRNA was synthesized and encapsulated into SM-102-based lipid nanoparticles (LNPs). VZV-primed middle-aged C57BL/6 mice were then subjected to homologous and heterologous prime-boost immunization strategies using VZV gE mRNA vaccine (RNA-gE) and protein subunit vaccine (PS-gE). The antigen-specific antibodies were evaluated using enzyme-linked immunosorbent assay (ELISA) analysis. Additionally, cell-mediated immunity (CMI) was detected using ELISPOT assay and flow cytometry. Besides, in vivo safety profiles were also evaluated and compared.

Results: The mRNA-loaded lipid nanoparticles had a hydrodynamic diameter of approximately 130 nm and a polydispersity index of 0.156. Total IgG antibody levels exhibited no significant differences among different immunization strategies. However, mice received 2×RNA-gE or RNA-gE>PS-gE showed a lower IgG1/IgG2c ratio than those received 2×PS-gE and PS-gE> RNA-gE. The CMI response induced by 2×RNA-gE or RNA-gE>PS-gE was significantly stronger than that induced by 2×PS-gE and PS-gE> RNA-gE. The safety evaluation indicated that both mRNA vaccine and protein vaccine induced a transient body weight loss in mice. Furthermore, the protein vaccine produced a notable inflammatory response at the injection sites, while the mRNA vaccine showed no observable inflammation.

Conclusion: The heterologous prime-boost strategy has demonstrated that an mRNA-primed immunization regimen can induce a better cell-mediated immune response than a protein subunit-primed regimen in middle-aged mice. These findings provide valuable insights into the design and optimization of VZV vaccines with the potentials to broaden varicella vaccination strategies in the future.

Keywords: cell-mediated immunity; glycoprotein E; heterologous prime-boost; lipid nanoparticles; mRNA vaccine; varicella-zoster Virus.

MeSH terms

  • Adjuvants, Immunologic* / administration & dosage
  • Animals
  • Antibodies, Viral / blood
  • Female
  • Herpes Zoster Vaccine / administration & dosage
  • Herpes Zoster Vaccine / immunology
  • Herpesvirus 3, Human / immunology
  • Immunity, Cellular*
  • Immunization, Secondary / methods
  • Liposomes
  • Mice
  • Mice, Inbred C57BL*
  • Nanoparticles* / chemistry
  • Vaccines, Subunit* / administration & dosage
  • Vaccines, Subunit* / immunology
  • Viral Envelope Proteins / administration & dosage
  • Viral Envelope Proteins / immunology
  • mRNA Vaccines

Substances

  • Vaccines, Subunit
  • Adjuvants, Immunologic
  • mRNA Vaccines
  • Lipid Nanoparticles
  • Antibodies, Viral
  • glycoprotein E, varicella-zoster virus
  • Viral Envelope Proteins
  • Herpes Zoster Vaccine
  • Liposomes